Trilaciclib

The addition of trilaciclib to chemotherapy did not improve OS among patients with metastatic triple-negative breast cancer, according to the agent’s manufacturer.

A phase 3 trial of trilaciclib in combination FOLFOXIRI and bevacizumab for patients with metastatic colorectal cancer met its co-primary endpoints but will be terminated based on early efficacy data, according to the agent’s manufacturer.

The FDA granted fast track designation to trilaciclib for use in combination with chemotherapy for treatment of locally advanced or metastatic triple-negative breast cancer, according to the agent’s manufacturer.

The FDA announced it approved a therapy to reduce the frequency of chemotherapy-related bone marrow suppression in adults with extensive-stage small cell lung cancer.

The FDA granted priority review to trilaciclib for treatment of patients with small cell lung cancer who are receiving chemotherapy, according to the agent’s manufacturer.